Back to School: How biopharma can reboot drug development. Access exclusive analysis here

House urges consistent CDER, CBER policies

Members of the House Energy and Commerce Committee on Friday released a letter to acting FDA Commissioner Lester Crawford criticizing the Center for Biologics

Read the full 242 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE